ENX 104
Alternative Names: ENX-104Latest Information Update: 27 Sep 2024
At a glance
- Originator Engrail Therapeutics
- Class Antidepressants; Benzamides; Heterocyclic compounds; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Major depressive disorder
Most Recent Events
- 18 Sep 2024 Phase-I clinical trials in Major depressive disorder (In volunteers) (PO)
- 15 Mar 2023 Engrail Therapeutics plans a phase I trial for Depressive disorders in 2024
- 15 Mar 2023 Preclinical trials in Depressive disorders in USA (PO) before March 2023 (Engrail Therapeutics pipeline, March 2023)